Tofacitinib as a novel salvage therapy for refractory T-cell large granular lymphocytic leukemia

Leukemia

Volumn 29, Issue 12, 2015, Pages 2427-2429

  Bilori, B ^a   Thota, S ^b   Clemente, M J ^b   Patel, B ^b   Jerez, A ^c   Afable, M ^b   Maciejewski, J P ^b  

^a WATERBURY HOSPITAL   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c HOSPITAL MORALES MESEGUER   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN; TOFACITINIB;

GENETICS; HUMAN; LEUKEMIA, LARGE GRANULAR LYMPHOCYTIC; MUTATION; SALVAGE THERAPY;

HUMANS; LEUKEMIA, LARGE GRANULAR LYMPHOCYTIC; MUTATION; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; SALVAGE THERAPY; STAT3 TRANSCRIPTION FACTOR;

EID: 84951567838     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.280     Document Type: Letter

References (15)

1. Zhang D, Loughran TP Jr. Large granular lymphocytic leukemia: molecular pathogenesis, clinical manifestations, and treatment. Hematology Am Soc Hematol Educ Program 2012; 2012: 652-659.
2. Bockorny B, Dasanu CA. Autoimmune manifestations in large granular lymphocyte leukemia. Clin Lymphoma Myeloma Leuk 2012; 12: 400-405.
3. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003; 423: 356-361.
4. Liu X, Loughran TP Jr. The spectrum of large granular lymphocyte leukemia and Felty's syndrome. Curr Opin Hematol 2011; 18: 254-259.
5. Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Investig 2001; 107: 351-362.
6. Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmäki H, Andersson EI, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 2012; 366: 1905-1913.
7. Watowich SS, Wu H, Socolovsky M, Klingmuller U, Constantinescu SN, Lodish HF. Cytokine receptor signal transduction and the control of hematopoietic cell development. Ann Rev Cell Dev Biol 1996; 12: 91-128.
8. Pesu M, Laurence A, Kishore N, Zwillich SH, Chan G, O'Shea JJ. Therapeutic targeting of Janus kinases. Immunol Rev 2008; 223: 132-142.
9. Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012; 367: 495-507.
10. Traynor K. FDA approves tofacitinib for rheumatoid arthritis. Am J Health Syst Pharm 2012; 69: 2120.
11. Shuai K, Liu B. Regulation of JAK-STAT signaling in the immune system. Nat Rev Immunol 2003; 3: 900-911.
12. Lamy T, Loughran TP Jr. How I treat T-LGL leukemia. Blood 2011; 117: 2764-2774.
13. Mohan SR, Clemente MJ, Afable M, Cazzolli HN, Bejanyan N, Wlodarski MW, et al. Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia. Haematologica 2009; 94: 1407-1414.
14. Clemente MJ, Wlodarski MW, Makishima H, Viny AD, Bretschneider I, Shaik M, et al. Clonal drift demonstrates unexpected dynamics of the T-cell repertoire in T-large granular lymphocyte leukemia. Blood 2011; 118: 4384-4393.
15. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010; 69: 1580-1588.